Epigenome-Driven Strategies for Personalized Cancer Immunotherapy

References

• Malayil R, Chhichholiya Y, Vasudeva K, et al. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes. Med Oncol. 2023;40(6):174. doi:10.1007/s12032-023-02037-2
   PubMed Web of Science ®Google Scholar
• Verma S, Sahu BD, Mugale MN. Role of lncRNAs in hepatocellular carcinoma. Life Sci. 2023;121751. doi:10.1016/j.lfs.2023.121751
   PubMedGoogle Scholar
• Gaulton KJ, Preissl S, Ren B. Interpreting non-coding disease-associated human variants using single-cell epigenomics. Nat Rev Genet. 2023. doi:10.1038/s41576-023-00598-6
   Web of Science ®Google Scholar
• Park J, Chung C. Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma. Brain Tumor Res Treat. 2023;11(2):86–93. doi:10.14791/btrt.2023.0011
   PubMedGoogle Scholar
• Alam J, Huda MN, Tackett AJ, Miah S. Oncogenic signaling-mediated regulation of chromatin during tumorigenesis. Cancer Metastasis Rev. 2023. doi:10.1007/s10555-023-10104-3
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249–253. doi:10.1038/nature15520
   PubMed Web of Science ®Google Scholar
• Khan ANH, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008;57(5):647–654. doi:10.1007/s00262-007-0402-4
   PubMed Web of Science ®Google Scholar
• Sundar R, Huang KK, Qamra A, et al. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Ann Oncol off J Eur Soc Med Oncol. 2019;30(3):424–430. doi:10.1093/annonc/mdy550
   PubMed Web of Science ®Google Scholar
• Iyer M, Anand U, Thiruvenkataswamy S, et al. A review of chromium (Cr) epigenetic toxicity and health hazards. Sci Total Environ. 2023;882:163483. doi:10.1016/j.scitotenv.2023.163483
   PubMed Web of Science ®Google Scholar
• Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Cybulski C, Tretyn A. Harnessing Epigenetics for Breast Cancer Therapy: the Role of DNA Methylation, Histone Modifications, and MicroRNA. Int J Mol Sci. 2023;24(8). doi:10.3390/ijms24087235
   Web of Science ®Google Scholar
• Zingg D, Arenas-Ramirez N, Sahin D, et al. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. Cell Rep. 2017;20(4):854–867. doi:10.1016/j.celrep.2017.07.007
   PubMed Web of Science ®Google Scholar
• Woods DM, Sodré AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res. 2015;3(12):1375–1385. doi:10.1158/2326-6066.CIR-15-0077-T
   PubMed Web of Science ®Google Scholar
• Villanueva L, Álvarez-Errico D, Esteller M. The Contribution of Epigenetics to Cancer Immunotherapy. Trends Immunol. 2020;41(8):676–691. doi:10.1016/j.it.2020.06.002
   PubMed Web of Science ®Google Scholar
• Liu L, Toung JM, Jassowicz AF, et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol off J Eur Soc Med Oncol. 2018;29(6):1445–1453. doi:10.1093/annonc/mdy119
   PubMed Web of Science ®Google Scholar
• Goyal A, Bauer J, Hey J, et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun. 2023;14(1):6731. doi:10.1038/s41467-023-42417-w
   PubMed Web of Science ®Google Scholar
• Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015;162(5):974–986. doi:10.1016/j.cell.2015.07.011
   PubMed Web of Science ®Google Scholar
• Kakoty V, Kc S, Kumari S, et al. Brain insulin resistance linked Alzheimer’s and Parkinson’s disease pathology: an undying implication of epigenetic and autophagy modulation. Inflammopharmacology. 2023;31(2):699–716. doi:10.1007/s10787-023-01187-z
   PubMed Web of Science ®Google Scholar
• Ferreira LL, Couto R, Oliveira PJ. Bisphenol A as epigenetic modulator: setting the stage for carcinogenesis? Eur J Clin Invest. 2015;45(Suppl 1):32–36. doi:10.1111/eci.12362
   PubMedGoogle Scholar
• Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1):248. doi:10.1038/s41467-017-02630-w
   PubMed Web of Science ®Google Scholar
• Mortaezaee K, Majidpoor J. Mechanisms of CD8(+) T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1. Biomed Pharmacother. 2023;163:114824. doi:10.1016/j.biopha.2023.114824
   PubMed Web of Science ®Google Scholar
• Mutlu H, Bozcuk H, Artaç M, Eser I. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: a classical and network meta-analysis. J Cancer Res Ther. 2023;19(Supplement):S6–S11. doi:10.4103/jcrt.jcrt_721_21
   PubMedGoogle Scholar
• Shuptrine CW, Perez VM, Selitsky SR, Schreiber TH, Fromm G. Shining a LIGHT on myeloid cell targeted immunotherapy. Eur J Cancer. 2023;187:147–160. doi:10.1016/j.ejca.2023.03.040
   PubMed Web of Science ®Google Scholar
• Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308. doi:10.3389/fimmu.2023.1133308
   PubMedGoogle Scholar
• Desai NV, Tan AR. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline BRCA1/2-Mutated Breast Cancers in the High-Risk, Early-Stage Setting. JCO Precis Oncol. 2023;7:e2200446. doi:10.1200/PO.22.00446
   PubMedGoogle Scholar
• Sheng J, Pan H, Han W. Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature. Front Immunol. 2023;14:1181444. doi:10.3389/fimmu.2023.1181444
   PubMed Web of Science ®Google Scholar
• Youngblood B, Oestreich KJ, S-J H, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity. 2011;35(3):400–412. doi:10.1016/j.immuni.2011.06.015
   PubMed Web of Science ®Google Scholar
• McPherson RC, Konkel JE, Prendergast CT, et al. Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy. Elife. 2014:3. doi:10.7554/eLife.03416
   Web of Science ®Google Scholar
• Youngblood B, Noto A, Porichis F, et al. Cutting edge: prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol. 2013;191(2):540–544. doi:10.4049/jimmunol.1203161
   PubMed Web of Science ®Google Scholar
• Creyghton MP, Cheng AW, Welstead GG, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010;107(50):21931–21936. doi:10.1073/pnas.1016071107
   PubMed Web of Science ®Google Scholar
• Austin JW, Lu P, Majumder P, Ahmed R, Boss JM. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J Immunol. 2014;192(10):4876–4886. doi:10.4049/jimmunol.1302750
   PubMed Web of Science ®Google Scholar
• Ma X, Wu J, Wang B, Liu C, Liu L, Sun C. Epigenetic modifications: critical participants of the PD-L1 regulatory mechanism in solid tumors (Review). Int J Oncol. 2022;61(5). doi:10.3892/ijo.2022.5424
   Web of Science ®Google Scholar
• Wang H, Fu C, Du J, et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer Res. 2020;39(1):29. doi:10.1186/s13046-020-1536-x
   PubMed Web of Science ®Google Scholar
• Deng S, Hu Q, Zhang H, Yang F, Peng C, Huang C. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy. Mol Cancer Ther. 2019;18(5):900–908. doi:10.1158/1535-7163.MCT-18-1068
   PubMed Web of Science ®Google Scholar
• Mondello P, Tadros S, Teater M, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10(3):440–459. doi:10.1158/2159-8290.CD-19-0116
   PubMed Web of Science ®Google Scholar
• Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128–134. doi:10.1038/nm.4036
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang -X-X, Wu W, et al. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells. Biochem Biophys Res Commun. 2019;517(2):201–209. doi:10.1016/j.bbrc.2019.07.039
   PubMed Web of Science ®Google Scholar
• Chen S, Youhong T, Tan Y, et al. EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2. Carcinogenesis. 2020;41(6):863–864. doi:10.1093/carcin/bgaa023
   PubMed Web of Science ®Google Scholar
• Wang X, Liang C, Yao X, et al. Corrigendum: PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC. Front Pharmacol. 2021;12:724799. doi:10.3389/fphar.2021.724799
   PubMed Web of Science ®Google Scholar
• Forterre A, Komuro H, Aminova S, Harada M. A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. Cancers. 2020;12(7). doi:10.3390/cancers12071852
   PubMed Web of Science ®Google Scholar
• Cortez MA, Anfossi S, Ramapriyan R, et al. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58(4):244–253. doi:10.1002/gcc.22725
   PubMed Web of Science ®Google Scholar
• Tang D, Zhao D, Wu Y, et al. The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer. J Cell Mol Med. 2018;22(8):3847–3856. doi:10.1111/jcmm.13657
   PubMed Web of Science ®Google Scholar
• Xia R, Geng G, Yu X, et al. LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs. J Immunother Cancer. 2021;9(8). doi:10.1136/jitc-2021-002746
   Web of Science ®Google Scholar
• Jo H, Shim K, Jeoung D. Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics. Int J Mol Sci. 2022;23(11). doi:10.3390/ijms23115881
   Web of Science ®Google Scholar
• Vafadar A, Shabaninejad Z, Movahedpour A, et al. Long Non-Coding RNAs As Epigenetic Regulators in Cancer. Curr Pharm Des. 2019;25(33):3563–3577. doi:10.2174/1381612825666190830161528
   PubMed Web of Science ®Google Scholar
• Yi K, Cui X, Liu X, et al. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Front Immunol. 2021;12:802795. doi:10.3389/fimmu.2021.802795
   PubMed Web of Science ®Google Scholar
• Fan Y, Dong X, Li M, et al. LncRNA KRT19P3 Is Involved in Breast Cancer Cell Proliferation, Migration and Invasion. Front Oncol. 2021;11:799082. doi:10.3389/fonc.2021.799082
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang N, Song P, et al. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020;53(9):e12855. doi:10.1111/cpr.12855
   PubMed Web of Science ®Google Scholar
• Yin L, Tang Y, Yuan Y. An Overview of the Advances in Research on the Molecular Function and Specific Role of Circular RNA in Cardiovascular Diseases. Biomed Res Int. 2022;2022:5154122. doi:10.1155/2022/5154122
   PubMed Web of Science ®Google Scholar
• Wang S, Qian L, Cao T, et al. Advances in the Study of CircRNAs in Tumor Drug Resistance. Front Oncol. 2022;12:868363. doi:10.3389/fonc.2022.868363
   PubMed Web of Science ®Google Scholar
• Li C, Zhang J, Yang X, et al. hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527. Cell Death Dis. 2021;12(9):807. doi:10.1038/s41419-021-04095-8
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81. doi:10.1016/S0065-2776(06)90002-9
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:Suppl:S185–S198. doi:10.1016/j.semcancer.2015.03.004
   Web of Science ®Google Scholar
• Smith KM, Desai J. Nivolumab for the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2018;18(7):611–618. doi:10.1080/14737140.2018.1480942
   PubMed Web of Science ®Google Scholar
• Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9(5):467–475. doi:10.1016/S2213-2600(20)30391-X
   PubMed Web of Science ®Google Scholar
• Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020;9(3). doi:10.3390/antib9030034
   Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856. doi:10.1158/2326-6066.CIR-14-0040
   PubMed Web of Science ®Google Scholar
• Robert C, V LG, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi:10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Monk BJ, Enomoto T, Kast WM, et al. Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials. Cancer Treat Rev. 2022;106:102385. doi:10.1016/j.ctrv.2022.102385
   PubMed Web of Science ®Google Scholar
• Yun JW, Kwon J, Lim T. Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: case Report and Review of the Literature. Medicina (Kaunas). 2023;59(2). doi:10.3390/medicina59020325
   Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–591. doi:10.1038/nrc2403
   PubMed Web of Science ®Google Scholar
• Marchetti C, Muzii L, Romito A, Benedetti Panici P. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;12:1095–1103. doi:10.2147/OTT.S155425
   PubMed Web of Science ®Google Scholar
• Dhillon S. Isatuximab: first Approval. Drugs. 2020;80(9):905–912. doi:10.1007/s40265-020-01311-1
   PubMed Web of Science ®Google Scholar
• Deckert J, Wetzel M-C, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res an off J Am Assoc Cancer Res. 2014;20(17):4574–4583. doi:10.1158/1078-0432.CCR-14-0695
   PubMed Web of Science ®Google Scholar
• Shukla SA, Bachireddy P, Schilling B, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018;173(3):624–633.e8. doi:10.1016/j.cell.2018.03.026
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450). doi:10.1126/scitranslmed.aar3342
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Han J, Duan J, Bai H, et al. TCR Repertoire Diversity of Peripheral PD-1(+)CD8(+) T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):146–154. doi:10.1158/2326-6066.CIR-19-0398
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014:515(7528):568–571. doi:10.1038/nature13954
   Web of Science ®Google Scholar
• Sade-Feldman M, Kanterman J, Klieger Y, et al. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clin Cancer Res an off J Am Assoc Cancer Res. 2016;22(23):5661–5672. doi:10.1158/1078-0432.CCR-15-3104
   PubMed Web of Science ®Google Scholar
• Neubert NJ, Schmittnaegel M, Bordry N, et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018;10(436). doi:10.1126/scitranslmed.aan3311
   PubMed Web of Science ®Google Scholar
• De Carvalho DD, Sharma S, You JS, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell. 2012;21(5):655–667. doi:10.1016/j.ccr.2012.03.045
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Lin K-T, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574(7777):273–277. doi:10.1038/s41586-019-1618-0
   PubMed Web of Science ®Google Scholar
• Orouji E, Federico A, Larribère L, et al. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. Int, J, Cancer. 2019;145(12):3462–3477. doi:10.1002/ijc.32432
   PubMed Web of Science ®Google Scholar
• Giacopelli B, Zhao Q, Ruppert AS, et al. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019;134(8):688–698. doi:10.1182/blood.2019000490
   PubMed Web of Science ®Google Scholar
• Bueno-Costa A, Piñeyro D, Soler M, et al. B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation. Leukemia. 2020;34(4):1158–1162. doi:10.1038/s41375-019-0643-1
   PubMed Web of Science ®Google Scholar
• Aznar MA, Labiano S, Diaz-Lagares A, et al. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8(+) T Cell-Relevant Genes. Cancer Immunol Res. 2018;6(1):69–78. doi:10.1158/2326-6066.CIR-17-0159
   PubMed Web of Science ®Google Scholar
• Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2019;20(2):109–127. doi:10.1038/s41576-018-0074-2
   PubMed Web of Science ®Google Scholar
• Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med. 2018;6(10):771–781. doi:10.1016/S2213-2600(18)30284-4
   PubMed Web of Science ®Google Scholar
• Berglund A, Mills M, Putney RM, Hamaidi I, Mulé J, Kim S. Methylation of immune synapse genes modulates tumor immunogenicity. J Clin Invest. 2020;130(2):974–980. doi:10.1172/JCI131234
   PubMed Web of Science ®Google Scholar
• Burr ML, Sparbier CE, Chan KL, et al. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019;36(4):385–401.e8. doi:10.1016/j.ccell.2019.08.008
   PubMed Web of Science ®Google Scholar
• Qamra A, Xing M, Padmanabhan N, et al. Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discov. 2017;7(6):630–651. doi:10.1158/2159-8290.CD-16-1022
   PubMed Web of Science ®Google Scholar
• Fröhlich A, Loick S, Bawden EG, et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 2020;52:102647. doi:10.1016/j.ebiom.2020.102647
   PubMed Web of Science ®Google Scholar
• Vogt TJ, Gevensleben H, Dietrich J, et al. Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5’-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients. Oncoimmunology. 2018;7(8):e1452579. doi:10.1080/2162402X.2018.1452579
   PubMed Web of Science ®Google Scholar
• Ghoneim HE, Fan Y, Moustaki A, et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017;170(1):142–157.e19. doi:10.1016/j.cell.2017.06.007
   PubMed Web of Science ®Google Scholar
• Hartana CA, Ahlén Bergman E, Broomé A, et al. Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clin Exp Immunol. 2018;194(1):39–53. doi:10.1111/cei.13183
   PubMed Web of Science ®Google Scholar
• Lingohr P, Dohmen J, Semaan A, et al. Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas. Epigenomics. 2019;11(6):639–653. doi:10.2217/epi-2018-0149
   PubMed Web of Science ®Google Scholar
• Dangaj D, Bruand M, Grimm AJ, et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell. 2019;35(6):885–900.e10. doi:10.1016/j.ccell.2019.05.004
   PubMed Web of Science ®Google Scholar
• Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019;10(1):2416. doi:10.1038/s41467-019-10369-9
   PubMedGoogle Scholar
• Brennan K, Shin JH, Tay JK, et al. NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. Sci Rep. 2017;7(1):17064. doi:10.1038/s41598-017-17298-x
   PubMedGoogle Scholar
• Sheng W, LaFleur MW, Nguyen TH, et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018;174(3):549–563.e19. doi:10.1016/j.cell.2018.05.052
   PubMed Web of Science ®Google Scholar
• Jung H, Kim HS, Kim JY, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10(1):4278. doi:10.1038/s41467-019-12159-9
   PubMedGoogle Scholar
• Goltz D, Gevensleben H, Vogt TJ, et al. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. JCI Insight. 2018;3(13). doi:10.1172/jci.insight.96793
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiang C, Wang Y, Duan Y, Liu C, Zhang Y. PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. Oncotarget. 2017;8(60):101535–101544. doi:10.18632/oncotarget.21328
   PubMedGoogle Scholar
• Fraietta JA, Nobles CL, Sammons MA, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307–312. doi:10.1038/s41586-018-0178-z
   PubMed Web of Science ®Google Scholar
• Chakravarthy A, Furness A, Joshi K, et al. Pan-cancer deconvolution of tumour composition using DNA methylation. Nat Commun. 2018;9(1):3220. doi:10.1038/s41467-018-05570-1
   PubMedGoogle Scholar
• Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9(1):4692. doi:10.1038/s41467-018-06654-8
   PubMed Web of Science ®Google Scholar
• Gray SM, Amezquita RA, Guan T, Kleinstein SH, Kaech SM. Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8(+) T Cell Terminal Differentiation and Loss of Multipotency. Immunity. 2017;46(4):596–608. doi:10.1016/j.immuni.2017.03.012
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Fratta E, Coral S, Maio M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther. 2014;142(3):339–350. doi:10.1016/j.pharmthera.2013.12.015
   PubMed Web of Science ®Google Scholar
• Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res. 2016;76(7):1683–1689. doi:10.1158/0008-5472.CAN-15-2125
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Topper MJ, Vaz M, Chiappinelli KB, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell. 2017;171(6):1284–1300.e21. doi:10.1016/j.cell.2017.10.022
   PubMed Web of Science ®Google Scholar
• Knox T, Sahakian E, Banik D, et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep. 2019;9(1):6136. doi:10.1038/s41598-019-42237-3
   PubMedGoogle Scholar
• Fratta E, Coral S, Covre A, et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011;5(2):164–182. doi:10.1016/j.molonc.2011.02.001
   PubMed Web of Science ®Google Scholar
• Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’-deoxycytidine. Cancer Res. 1994;54(7):1766–1771.
   PubMed Web of Science ®Google Scholar
• Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene. 2006;25(20):2873–2884. doi:10.1038/sj.onc.1209319
   PubMed Web of Science ®Google Scholar
• Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res. 2006;4(5):339–349. doi:10.1158/1541-7786.MCR-05-0229
   PubMed Web of Science ®Google Scholar
• Ritter C, Fan K, Paschen A, et al. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017;7(1):2290. doi:10.1038/s41598-017-02608-0
   PubMedGoogle Scholar
• Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol. 2007;178(2):692–696. doi:10.1016/j.juro.2007.03.109
   PubMed Web of Science ®Google Scholar
• Roulois D, Loo Yau H, Singhania R, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015;162(5):961–973. doi:10.1016/j.cell.2015.07.056
   PubMed Web of Science ®Google Scholar
• Fukumoto T, Fatkhutdinov N, Zundell JA, et al. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Cancer Res. 2019;79(21):5482–5489. doi:10.1158/0008-5472.CAN-19-1302
   PubMed Web of Science ®Google Scholar